Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Investigator-Initiated Exploratory Study of Sacituzumab Tirumotecan for Previously Treated Unresectable Thymic Carcinomas

NCT07750353 is registered in ClinicalTrials.gov with National Cancer Center, Japan as lead sponsor.

NCT NCT07750353
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07750353 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Investigator-Initiated Exploratory Study of Sacituzumab Tirumotecan for Previously Treated Unresectable Thymic Carcinomas
Lead sponsor
National Cancer Center, Japan
Phase
Phase 2
Overall status
Not yet recruiting
Start date
February 1, 2027
Completion date
June 30, 2030
Enrollment
35 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable thymic carcinoma